PregLem SA

07.10.2010 – 10:24
Richter Announces the Acquisition of PregLem
Budapest, Hungary (ots/PRNewswire) - Richter announces the Acquisition of PregLem for an initial cash consideration of CHF150 million (EUR114 million) and further milestone payments of up to CHF295 million (EUR223 million). The Acquisition values PregLem at up to CHF445 million (EUR337 million) - PregLem is a Swiss based, specialty biopharmaceutical company focused on the development and commercialisation of ...
mehr
03.06.2010 – 09:12
PregLem announces positive phase III results for Esmya[TM]
Geneva (ots) - PEARL I trial meets primary efficacy and safety endpoints / PregLem preparing for submission to the European Medicines Agency in 2010 PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine ...
mehr